CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MEL-PLEX focuses on developing personalized therapies for resistant cancers like malignant melanoma through interdisciplinary research. By combining biomedical and computational approaches, the project aims to enhance understanding of disease mechanisms and create predictive models for treatment responsiveness.
Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous and chemotherapy resistant cancers, such as malignant melanoma.
This can only be achieved by industry-academia collaborations in newly emerging, innovative research disciplines such as translational cancer systems biology and systems medicine.
These disciplines and the associated European training needs provide the foundation for the MEL-PLEX ETN. MEL-PLEX ai…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Dresden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Luxembourg, ESCH-SUR-ALZETTE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Belgium, Leuven
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Heidelberg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
